Division of Medical Oncology, AUSL Viterbo, Belcolle Hospital, Viterbo, Italy.
Department of Oncology & Hematology, Azienda Ospedaliero Universitaria Policlinico di Modena, Modena, Italy.
Future Oncol. 2017 Jul;13(17):1517-1525. doi: 10.2217/fon-2017-0062. Epub 2017 Apr 21.
Quality of life (QoL) is a critical issue for women with metastatic breast cancer (MBC). Eribulin mesylate represents a novel and active drug for pretreated MBC. Regretfully, few data exploring health-related (HR) QoL are available in unselected populations.
PATIENTS & METHODS: A multicenter prospective observational study was conducted in 50 MBC patients treated with eribulin mesylate, in order to evaluate HRQoL and patients' well-being by using the Edmonton symptoms assessment scale (ESAS) and Functional Assessment of Cancer Therapy-Breast questionnaires.
A significant ESAS score improvement was observed with a 10% median decrease. No differences were revealed for the QoL scores.
The analysis of ESAS and Functional Assessment of Cancer Therapy scores showed that eribulin mesylate contributes to preserve QoL in MBC patients.
生活质量（QoL）是转移性乳腺癌（MBC）女性的关键问题。甲磺酸艾日布林是一种用于预处理 MBC 的新型有效药物。遗憾的是，在未选择的人群中，很少有关于健康相关（HR）QoL 的数据可用。
对 50 例接受甲磺酸艾日布林治疗的 MBC 患者进行了一项多中心前瞻性观察研究，以使用埃德蒙顿症状评估量表（ESAS）和癌症治疗功能评估-乳房问卷评估 HRQoL 和患者的幸福感。
ESAS 评分有显著改善，中位数下降 10%。QoL 评分无差异。
对 ESAS 和癌症治疗功能评估评分的分析表明，甲磺酸艾日布林有助于维持 MBC 患者的 QoL。
